Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer

home / precision-medicine / expanding-options-for-relapsed-refractory-her2-metastatic-breast-cancer

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Treatment Options in HER2+ Metastatic Breast Cancer

EP. 1: Treatment Options in HER2+ Metastatic Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Trastuzumab Emtansine in HER2+ Breast Cancer

EP. 2: Trastuzumab Emtansine in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Options in Breast Cancer After HER2+ Targeted Therapy

EP. 3: Options in Breast Cancer After HER2+ Targeted Therapy

Targeted Oncology
July 7th 2020

Watch

Trastuzumab Deruxtecan in HER2+ Breast Cancer

EP. 4: Trastuzumab Deruxtecan in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Neratinib + Capecitabine in HER2+ Breast Cancer

EP. 5: Neratinib + Capecitabine in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Understanding HER2CLIMB Clinical Trial

EP. 6: Understanding HER2CLIMB Clinical Trial

Targeted Oncology
July 7th 2020

Watch

Toxicity Management When Using HER2CLIMB Regimen

EP. 7: Toxicity Management When Using HER2CLIMB Regimen

Targeted Oncology
July 7th 2020

Watch

Next-Generation Sequencing in HER2+ Breast Cancer

EP. 8: Next-Generation Sequencing in HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch

Newly Approved Agents for HER2+ Breast Cancer

EP. 9: Newly Approved Agents for HER2+ Breast Cancer

Targeted Oncology
July 7th 2020

Watch